Entry-into-humans study with ACT-462206, a novel dual orexin receptor antagonist, comparing its pharmacodynamics with almorexant

Journal of Clinical Pharmacology

Volumn 54, Issue 9, 2014, Pages 979-986

  Hoch, Matthias ^a   Van Gorsel, Helene ^b   Van Gerven, Joop ^b   Dingemanse, Jasper ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

^b CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

Author keywords

almorexant; orexin; pharmacodynamics; pharmacokinetics; sleep disorders

Indexed keywords

ACT 462206; ALMOREXANT; DUAL OREXIN RECEPTOR ANTAGONIST; OREXIN RECEPTOR; PEPTIDE DERIVATIVE; PLACEBO; UNCLASSIFIED DRUG; ZOLPIDEM; ACETAMIDE DERIVATIVE; ACT-462206; HYPNOTIC SEDATIVE AGENT; ISOQUINOLINE DERIVATIVE; PYRROLIDINE DERIVATIVE; SULFONAMIDE;

ALERTNESS; ARTICLE; ASTHENIA; BLURRED VISION; CONTROLLED STUDY; DIPLOPIA; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERANCE; DRUG USE; FATIGUE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; MOTOR COORDINATION; NORMAL HUMAN; PHARMACODYNAMICS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; VISUAL ANALOG SCALE; VISUAL IMPAIRMENT; ADOLESCENT; ADULT; ANTAGONISTS AND INHIBITORS; ATTENTION; BLOOD; BODY EQUILIBRIUM; DRUG EFFECTS; PSYCHOMOTOR PERFORMANCE; SACCADIC EYE MOVEMENT; SLEEP STAGE; WAKEFULNESS; YOUNG ADULT;

ACETAMIDES; ADOLESCENT; ADULT; ATTENTION; DOUBLE-BLIND METHOD; HUMANS; HYPNOTICS AND SEDATIVES; ISOQUINOLINES; MALE; OREXIN RECEPTORS; POSTURAL BALANCE; PSYCHOMOTOR PERFORMANCE; PYRROLIDINES; SACCADES; SLEEP STAGES; SULFONAMIDES; WAKEFULNESS; YOUNG ADULT;

EID: 84905586594     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.297     Document Type: Article

References (25)

1. de Lecea L, Kilduff TS, Peyron C, et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA. 1998; 95: 322-327.
2. Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 1998; 92: 573-585.
3. Kilduff TS, Peyron C,. The hypocretin/orexin ligand-receptor system: implications for sleep and sleep disorders. Trends Neurosci. 2000; 23: 359-365.
4. Sakurai T,. Roles of orexin/hypocretin in regulation of sleep/wakefulness and energy homeostasis. Sleep Med Rev. 2005; 9: 231-241.
5. Ferguson AV, Samson WK,. The orexin/hypocretin system: a critical regulator of neuroendocrine and autonomic function. Front Neuroendocrinol. 2003; 24: 141-150.
6. Mahler SV, Smith RJ, Moorman DE, Sartor GC, Aston-Jones G,. Multiple roles for orexin/hypocretin in addiction. Prog. Brain Res. 2012; 198: 79-121.
7. Nishino S,. The hypocretin/orexin receptor: therapeutic prospective in sleep disorders. Expert Opin Investig Drugs. 2007; 16: 1785-1797.
8. Coleman PJ, Renger JJ,. Orexin receptor antagonists: a review of promising compounds patented since 2006. Expert Opin Ther Pat. 2010; 20: 307-324.
9. Dündar Y, Dodd S, Strobl J, Boland A, Dickson R, Walley T,. Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and meta-analysis. Hum Psychopharmacol. 2004; 19: 305-322.
10. Lieberman JA,. Update on the safety considerations in the management of insomnia with hypnotics: incorporating modified-release formulations into primary care. Prim Care Companion J Clin Psychiatry. 2007; 9: 25-31.
11. Hoever P, Dorffner G, Beneš H, et al. Orexin receptor antagonism, a new sleep-enabling paradigm: a proof-of-concept clinical trial. Clin Pharmacol Ther. 2012; 91: 975-985.
12. Winrow CJ, Renger JJ,. Discovery and development of orexin receptor antagonists as therapeutics for insomnia. Br J Pharmacol. 2013, DOI: 10.1111/bph.12261.
13. Mieda M, Sakurai T,. Orexin (hypocretin) receptor agonists and antagonists for treatment of sleep disorders. Rationale for development and current status. CNS Drugs. 2013; 27: 83-90.
14. Hoever P, de Haas S, Winkler J, et al. Orexin receptor antagonism, a new sleep-promoting paradigm: an ascending single-dose study with almorexant. Clin Pharmacol Ther. 2010; 87: 593-600.
15. Hoever P, de Haas SL, Dorffner G, Chiossi E, van Gerven JM, Dingemanse J,. Orexin receptor antagonism: an ascending multiple-dose study with almorexant. J Psychopharmacol. 2012; 26: 1071-1080.
16. Borland RG, Nicholson AN,. Comparison of the residual effects of two benzodiazepines (nitrazepam and flurazepam hydrochloride) and pentobarbitone sodium on human performance. Br J Clin Pharmacol. 1975; 2: 9-17.
17. Borland RG, Nicholson AN,. Visual motor co-ordination and dynamic visual acuity. Br J Clin Pharmacol. 1984; 18 (Suppl 1): 69S-72S.
18. Norris H,. The action of sedatives on brain stem oculomotor systems in man. Neuropharmacology. 1971; 10: 181-191.
19. de Visser SJ, van der Post J, Pieters MS, et al. Biomarkers for the effects of antipsychotic drugs in healthy volunteers. Br J Clin Pharmacol. 2001; 51: 119-132.
20. Bond A, Lader M,. The use of analogue scales in rating subjective feelings. Br J Med Psychol. 1974; 47: 211-218.
21. Gough K, Hutchison M, Keene O, et al. Assessment of dose proportionality: report from the statisticians in the pharmaceutical industry/pharmacokinetics UK joint working party. Drug Inform J. 1995; 29: 1039-1048.
22. Hoch M, Hoever P, Zisowsky J, Priestley A, Fleet D, Dingemanse J,. Absolute oral bioavailability of almorexant, a dual orexin receptor antagonist, in healthy human subjects. Pharmacology. 2012; 89: 53-57.
23. Ambre JJ, Belknap SM, Nelson J, Ruo TI, Shin S, Atkinson AJ,. Acute tolerance to cocaine in humans. Clin Pharmacol Ther. 1988; 44: 1-8.
24. Fattinger K, Verotta D, Benowitz NL,. Pharmacodynamics of acute tolerance to multiple nicotinic effects in humans. J Pharmacol Exp Ther. 1997; 281: 1238-1246.
25. Dingemanse J, Häussler J, Hering W, Ihmsen H, Albrecht S, Zell M, Schwilden H, Schüttler J,. Pharmacokinetic-pharmacodynamic modelling of the EEG effects of Ro 48-6791, a new short-acting benzodiazepine, in young and elderly subjects. Br J Anaesth. 1997; 79: 567-574.